Is FUJIY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Bio CDMO scale-up at Holly Springs and Denmark, with revenue (ttm) at ~¥3.43 trillion (~$21.8 billion). The bear case rests on the largest near-term risk is Bio CDMO execution. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The largest near-term risk is Bio CDMO execution. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Bio CDMO scale-up at Holly Springs and Denmark. Fujifilm has spent several hundred billion yen building large-scale cell culture capacity for biologic drugs, anchored by the Holly Springs, North Carolina campus and an expanded site in Hillerod, Denmark.

The largest near-term risk is Bio CDMO execution. Regulatory inspection pauses at US plants and delayed profitability at Holly Springs already forced a ~¥28 billion cut to the Healthcare profit target, and further FDA observations, customer program cancellations or slower utilization would extend losses on a very large fixed-cost base. Electronics is cyclical and tied to chipmakers' capex and inventory swings, so a semiconductor downturn would hit the segment currently carrying the group. Currency is a two-way risk for ADR holders: a weaker yen flatters reported yen profits but lowers the dollar value of each ADR, while a sharp yen rally would reverse recent translation gains. US tariffs and higher raw material and energy costs (management flagged Middle East tensions) pressure margins. Business Innovation is a structurally declining office-print market, and a spin-off could disappoint. Finally, FUJIY trades over the counter with thinner liquidity and wider spreads than the Tokyo line, and dividends are paid in yen, converted, and may face Japanese withholding tax.

FUJIFILM Holdings is best known for photographic film, but healthcare, materials and business imaging now drive most of its ~¥3.4 trillion revenue.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Bio CDMO scale-up at Holly Springs and Denmark) stalling in the reported numbers rather than in the narrative, the risk above (the largest near-term risk is Bio CDMO execution) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

FUJIY is the ticker for FUJIFILM Holdings' American Depositary Receipt, which trades over the counter in the United States in US dollars. The underlying company is listed on the Tokyo Stock Exchange under code 4901. Each FUJIY ADR represents half of one ordinary Tokyo share, so two ADRs equal one share. In late October 2026 the ADR traded near ~$10.83 while the Tokyo shares were around ¥3,416, which, at roughly ¥157 per dollar, lines up with that 0.5 ratio. A separate ticker, FUJIF, represents the ordinary shares themselves on the OTC market. The ADR lets US investors hold the company through a regular brokerage account, with dividends converted to dollars, though liquidity is thinner than on the Tokyo exchange and bid-ask spreads can be wider.

Fujifilm reinvented itself after digital photography collapsed the film market in the 2000s, applying its chemistry and coating expertise to new industries. Today it has four segments. Healthcare (medical imaging, life sciences and Bio CDMO drug manufacturing) is the largest strategic bet. Electronics sells semiconductor materials and data storage tape. Imaging, which includes instax instant cameras and X and GFX digital cameras, generated ~¥627 billion of revenue in the year ended March 2026 and is guided to be the biggest profit contributor this year. Business Innovation is the former Fuji Xerox office printing and document services business, about a quarter of sales. Traditional photographic film is now a minor part of the Imaging segment rather than the core of the company.

For the fiscal year ended March 2026, Fujifilm reported record revenue of ~¥3,357 billion (+5.0%), operating income of ~¥350.2 billion (+6.1%) and net income of ~¥276.7 billion (+6.0%). The June 2026 quarter, the latest reported as of late October 2026, showed record first-quarter revenue of ~¥826.5 billion (+10.3%) but operating income down ~32% to ¥51.2 billion. The drop came from a Healthcare operating loss tied to Bio CDMO inspection pauses and start-up costs, plus one-time Business Innovation restructuring. Electronics and Imaging both grew strongly. The company kept full-year guidance of ~¥365 billion operating income and ~¥280 billion net income. First-half results (April to September 2026) are expected in early November 2026 and will show whether the Healthcare drag has started to ease.